Navigation Links
New Phase IV Clinical Study Indicates LidoSite Provides,Rheumatology Patients Superior Pain Relief

FAIR LAWN, N.J.--(BUSINESS WIRE)--Mar 19, 2007 - Vyteris Holdings (Nevada), Inc. (OTCBB: VYHN), today announced results from a new phase IV "Open Label" clinical study demonstrating that LidoSite, the first FDA approved active patch for dermal analgesia, provided better pain relief to more than 73 percent of patients receiving injections of hyaluronic acid during treatment for osteoarthritis than usual topical analgesics.

"Treatment can be very painful, requiring multiple injections into sensitive joints, with many patients having a difficult time with this pain, leading some to avoid regular treatment," said Dr. Evan Liebowitz, a rheumatologist affiliated with Prospect Medical Office in Midland Park, NJ and Valley Hospital in Ridgewood, NJ. "Patients who avoid regular treatments for rheumatoid arthritis and osteoarthritis risk further loss of articular cartilage in the knee."

The study, involving six study sites and 14 physicians, followed 63 patients over the course of two routine injections of hyaluronic acid for the treatment of osteoarthritis.

During the first treatment, patients either received no local anesthesia or an alternate local anesthesia prior to cannulation or needle puncture. During the second treatment, patients received the LidoSite system, comprised of the LidoSite Patch and the LidoSite Controller. In the study more than 73 percent preferred LidoSite to the treatment used during their first visit. Additionally, the majority of rheumatology physicians surveyed were satisfied with LidoSite, compared to other available treatment options, such as ethyl chloride, lidocaine injections or fluormethane spray.

"This initial study demonstrates the acceptability among patients and rheumatologists for using LidoSite as an effective treatment regime for needle pain for the multiple injections arthritis requires, as well as its potential availability in the doctor's office setting."
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:5/22/2015)... , May 22, 2015 Today, ... central nervous system stimulant indicated for the treatment ... patients beginning Summer 2015. The ... received approval from the U.S. Food and Drug ... an extended-release formulation of methylphenidate capsule with an ...
(Date:5/22/2015)... LONDON , May 22, 2015 ... early phase clinical research unit with a worldwide ... respected for its frequent publications in peer reviewed ... and European stakeholders and regulators in discussions about ... results.      (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , ...
(Date:5/22/2015)... 22, 2015  China Nepstar Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based ... the resignation of Mr. Fuxiang Zhang as ... immediately. Ms. Rebecca Yingnan Zhang has been ... of directors, effective immediately. Meanwhile, Ms. Zhang resigned from ...
Breaking Medicine Technology:Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 2China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 3
... plc (Nasdaq: JAZZ ) today announced several ... company,s leadership team. The appointments include: ... company and will serve as general counsel and an ... in March.  Ms. Hooper is currently a partner at ...
... Sinovac Biotech Ltd. (Nasdaq: SVA ), a leading ... a letter dated January 18, 2012 from The Nasdaq Stock ... from the Company,s Board of Directors effective January 4, 2012, ... Nasdaq,s requirement that its audit committee consists of at least ...
Cached Medicine Technology:Jazz Pharmaceuticals plc Announces New Executive Appointments 2Sinovac Receives Nasdaq Deficiency Letter Regarding Audit Committee Requirement 2
(Date:5/25/2015)... MA (PRWEB) May 25, 2015 A recent ... 2015 states 1,000 persons have died as a direct result ... 2014. This marks a 33% rise in overdose deaths attributed ... Charlie Baker, “This issue doesn’t care about geography. This issue ... This issue doesn’t care about class.” As the state of ...
(Date:5/25/2015)... 25, 2015 Join Fiona's Soccer Camp at ... instructional clinic. Irish National Player, Fiona O'Sullivan will be ... a taste of her coaching style. Fiona has three camps ... in Novato are at Lynwood Elmentary School (June 15-19) and ... School - June 6th, 2015 - 1:00-3:00pm. Bring a Soccer ...
(Date:5/25/2015)... 2015 Decora Preset 60 Minute Countdown ... available on ‘The Hardware City.’ The product helps in automatically ... a time and the related electronic device is automatically turned ... of the company said, “We are glad that this amazing ... can buy Countdown Timer Switch in just a few clicks. ...
(Date:5/24/2015)... May 24, 2015 For people who ... Chinese Enterokinase Industry, 2009-2019 Market Research Report would be ... an exhaustive study on the present market scenario of ... into the growing Chinese market of this industry. The ... overall status of the manufacturers in this industry. The ...
(Date:5/24/2015)... New York, New York (PRWEB) May 24, 2015 ... of testosterone treatment lawsuits ( http://www.testosteronelawsuithub.com/ ) has ... discuss the progress of the multidistrict litigation. According ... Court, Northern District of Illinois, the Conference will ... p.m. (In re: Testosterone Replacement Therapy Product Liability ...
Breaking Medicine News(10 mins):Health News:Opioid Deaths Increase by 33 Percent Since 2012 in Mass. 2Health News:US Sports Camps and Nike Soccer Camps Offer Complimentary Instructional Clinic with Fiona's Soccer Camp 2Health News:Leviton's Decora 60 Minute Countdown Timer Available On ‘The Hardware City’ 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 4Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3
... , WEDNESDAY, May 18 (HealthDay News) -- Although ... offer no benefit to patients suffering from pulmonary arterial ... blood pressure in the arteries of the lungs, according ... by the U.S. National Institutes of Health, researchers divided ...
... By Jenifer Goodwin HealthDay Reporter , WEDNESDAY, ... younger are now being treated for autism in Massachusetts, a ... born between 2001 and 2005 was enrolled in early intervention ... according to the study. Over the five-year period, the ...
... absorbed from the sun, plays a role in protection against ... has shown that children who live in colder, wetter cities ... since there are fewer hours of sunlight in such places. ... it,s also dangerous to avoid it. There has to be ...
... associated with outsized, supercooled, superconducting magnets, is one of ... study everything from alcohols to proteins to such frontiers ... cousin, magnetic resonance imaging (MRI), is as loud as ... for a wide range of medical conditions. ...
... NYU Langone Medical Center, one of the nation,s premier academic ... Medicine, NYU Physician, is now available as a free iPad ... published three times a year, provides news and insights about ... Each issue features a trio of in-depth articles focused on ...
... ARBOR, Mich. About half of prostate cancers have a ... a new class of cancer-fighting drugs, a new study from ... drugs, called PARP inhibitors, are currently being tested in breast ... which are found in up to 10 percent of all ...
Cached Medicine News:Health News:Standard Heart Drugs Won't Ease Pulmonary Hypertension 2Health News:Massachusetts Study Shows Sharp Rise in Early Autism Diagnoses 2Health News:Massachusetts Study Shows Sharp Rise in Early Autism Diagnoses 3Health News:Sun protects against childhood asthma 2Health News:Nuclear magnetic resonance with no magnets 2Health News:Nuclear magnetic resonance with no magnets 3Health News:Nuclear magnetic resonance with no magnets 4Health News:Nuclear magnetic resonance with no magnets 5Health News:Nuclear magnetic resonance with no magnets 6Health News:Half of prostate cancers could potentially benefit from new type of cancer drugs, U-M study finds 2
Used to obtain biopsy specimens from pathological lesions in the ureter, renal pelvis, infundibula, or calyces. Supplied sterile in peel-open packages. Intended for one-time use....
Inquire...
Used to obtain tissue biopsy under direct vision. Cup Biopsy Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in peel-open packages. Intended for one-time use....
... Brasseler USA™ MicroLine™ Small Bone Power ... operation while performing under the most ... system developed for small bone osteotomies ... Sagittal Saw (Extended Length Available), Oscillating ...
Medicine Products: